News|Articles|October 9, 2026

Symptomatic Dermographism in Practice: What APPs Should Know About a New Treatment Option

NP/PA Connect

Symptomatic dermographism has its first on-label treatment. Here’s what APPs should know about recognition, treatment, and remibrutinib.

The approval of remibrutinib introduces a new treatment option for symptomatic dermographism and an opportunity for advanced practice providers to revisit recognition, assessment, and management of the chronic inducible urticaria subtype.

Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.